Pulmonary Arterial Hypertension

Kelly M. Chin, Lewis J. Rubin

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10 years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2 separate classes. Over this same period, the classification of pulmonary hypertension has been revised with changes including the substitution of the term idiopathic for primary PAH and an expanded list of conditions felt to be associated with the development of PAH. Long-term follow-up studies have provided better information on prognosis and expected outcomes with treatment, with particularly valuable data on reassessment of prognosis after treatment with epoprostenol. Combination therapy is more frequently being used, and limited data on novel therapies such as stem cell transplantation have been published. The purpose of this review is to describe the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH.

Original languageEnglish (US)
Pages (from-to)1527-1538
Number of pages12
JournalJournal of the American College of Cardiology
Volume51
Issue number16
DOIs
StatePublished - Apr 22 2008

Fingerprint

Pulmonary Hypertension
Epoprostenol
Therapeutics
Stem Cell Transplantation
Familial Primary Pulmonary Hypertension

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Pulmonary Arterial Hypertension. / Chin, Kelly M.; Rubin, Lewis J.

In: Journal of the American College of Cardiology, Vol. 51, No. 16, 22.04.2008, p. 1527-1538.

Research output: Contribution to journalArticle

Chin, Kelly M. ; Rubin, Lewis J. / Pulmonary Arterial Hypertension. In: Journal of the American College of Cardiology. 2008 ; Vol. 51, No. 16. pp. 1527-1538.
@article{fc08489b973c4390be83de128501c268,
title = "Pulmonary Arterial Hypertension",
abstract = "Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10 years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2 separate classes. Over this same period, the classification of pulmonary hypertension has been revised with changes including the substitution of the term idiopathic for primary PAH and an expanded list of conditions felt to be associated with the development of PAH. Long-term follow-up studies have provided better information on prognosis and expected outcomes with treatment, with particularly valuable data on reassessment of prognosis after treatment with epoprostenol. Combination therapy is more frequently being used, and limited data on novel therapies such as stem cell transplantation have been published. The purpose of this review is to describe the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH.",
author = "Chin, {Kelly M.} and Rubin, {Lewis J.}",
year = "2008",
month = "4",
day = "22",
doi = "10.1016/j.jacc.2008.01.024",
language = "English (US)",
volume = "51",
pages = "1527--1538",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "16",

}

TY - JOUR

T1 - Pulmonary Arterial Hypertension

AU - Chin, Kelly M.

AU - Rubin, Lewis J.

PY - 2008/4/22

Y1 - 2008/4/22

N2 - Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10 years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2 separate classes. Over this same period, the classification of pulmonary hypertension has been revised with changes including the substitution of the term idiopathic for primary PAH and an expanded list of conditions felt to be associated with the development of PAH. Long-term follow-up studies have provided better information on prognosis and expected outcomes with treatment, with particularly valuable data on reassessment of prognosis after treatment with epoprostenol. Combination therapy is more frequently being used, and limited data on novel therapies such as stem cell transplantation have been published. The purpose of this review is to describe the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH.

AB - Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10 years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2 separate classes. Over this same period, the classification of pulmonary hypertension has been revised with changes including the substitution of the term idiopathic for primary PAH and an expanded list of conditions felt to be associated with the development of PAH. Long-term follow-up studies have provided better information on prognosis and expected outcomes with treatment, with particularly valuable data on reassessment of prognosis after treatment with epoprostenol. Combination therapy is more frequently being used, and limited data on novel therapies such as stem cell transplantation have been published. The purpose of this review is to describe the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH.

UR - http://www.scopus.com/inward/record.url?scp=41949104810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949104810&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2008.01.024

DO - 10.1016/j.jacc.2008.01.024

M3 - Article

C2 - 18420094

AN - SCOPUS:41949104810

VL - 51

SP - 1527

EP - 1538

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 16

ER -